NCT06345287 - Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Head and Neck Cancer

Interventions

RADIATION

radical radiotherapy (60Gy)

concurrent chemoradiotherapy (60Gy) after induction therapy

RADIATION

radical radiotherapy (66Gy)

concurrent chemoradiotherapy (66Gy) after induction therapy

RADIATION

radical radiotherapy (70Gy)

concurrent chemoradiotherapy (70Gy) after induction therapy

COMBINATION_PRODUCT

anti-PD-1 or PD-L1 antibody

immunotherapy maintenance with anti-PD-1 or PDL1antibody every three weeks for 1 year after radiotherapy

Trial Locations (1)

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER